CPRX - Catalyst Pharmaceuticals Non-GAAP EPS of $0.26 beats by $0.07 revenue of $57.24M beats by $3.55M

• Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q3 Non-GAAP EPS of $0.26 beats by $0.07 .
• Revenue of $57.24M (+59.2% Y/Y) beats by $3.55M .
• FY2022 Guidance : The company has increased its forecast for total revenues to be in the range of between $205M and $210M, representing a 46% - 49% increase in total revenues compared to 2021 vs. consensus of $205.03M, with cash operating expenses to be in the range of $65M to $70M and non-GAAP net income expected to be in the range of $100M - $105M.

For further details see: